Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for CREXONT® has been accepted for review by Health Canada.

Knight files NDS for CREXONT in Canada - BioTuesdays

Knight Therapeutics (TSX: GUD) has announced that its new drug submission (NDS) for CREXONT—a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease—has been accepted for review by Health Canada. According to Knight, CREXONT is expected to compete in a market size of more than $50 million in Canada and $120 million in Brazil—each market with a $15 million controlled release portio…